Trials / Completed
CompletedNCT00154388
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 15 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib mesylate |
Timeline
- Start date
- 2001-02-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-09-12
- Last updated
- 2016-11-18
Source: ClinicalTrials.gov record NCT00154388. Inclusion in this directory is not an endorsement.